MedPath

PHARMATHEN S.A.

🇬🇷Greece
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:4
Completed:2

Trial Phases

2 Phases

Phase 1:2
Not Applicable:1

Drug Approvals

5

EMA:5

Drug Approvals

Memantine LEK

Authorization Status
Withdrawn
Approval Date
Apr 21, 2013
EMA

Matever

Authorization Status
Authorised
Approval Date
Oct 3, 2011
EMA

Iasibon

Authorization Status
Authorised
Approval Date
Jan 21, 2011
EMA

Grepid

Authorization Status
Authorised
Approval Date
Jul 27, 2009
EMA

Grepid

Authorization Status
Authorised
Approval Date
Jul 27, 2009
EMA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Not Applicable
1 (33.3%)

A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2018-02-07
Last Posted Date
2019-07-19
Lead Sponsor
Pharmathen S.A.
Target Recruit Count
70
Registration Number
NCT03425552
Locations
🇯🇴

Al-Esraa Hospital, Amman, Jordan

🇯🇴

King Abdullah University Hospital, Ar Ramtha, Jordan

🇯🇴

Princes Basma Teaching Hospital, Irbid, Jordan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.